IGF-1 LR3 vs MGF
Last updated: October 27, 2026 · 5 min read · By the Grey Peptides Editorial Board
- Both derive from IGF-1, but IGF-1 LR3 is a modified full-length IGF-1 1 and MGF is a short fragment from one splice variant of the IGF-1 gene 3.
- Neither has been given to a person in any published study 1. Everything known comes from cells and animals.
- Both are prohibited in sport 1, black-market IGF-1 analogues have been found oxidised 9, and the approved drug in this family, mecasermin, is a different molecule 1.
Side by side
IGF-1 LR3 Low and MGF Low both trace back to insulin-like growth factor 1 (IGF-1). WADA's 2026 List prohibits both under its growth factors section 1. The table is read from our encyclopedia entries.
| Field | IGF-1 LR3 | MGF |
|---|---|---|
| Encyclopedia entry | IGF-1 LR3 Full entry | MGF Mid-length entry |
| Molecule class | Protein, not a peptide | Peptide |
| Category | Research | Research |
| FDA status | Research Chemical | Research Chemical |
| Approved elsewhere | None recorded | None recorded |
| Evidence grade | Low | Low |
| Half-life | Not measured in people; rats clear it faster than IGF-1 | Shorter than systemic IGF-1's when unbound; not measured in people |
| Formula | C400H619N111O115S9 | Not stated |
| Molecular weight | 9,111.6 g/mol | Not stated |
| WADA 2026 | Prohibited at all times (S2.3) | Prohibited at all times (S2.3) |
| WADA 2027 | Prohibited at all times (S2.3) | Prohibited at all times (S2.3) |
| In one line | IGF-1 rebuilt so its binding proteins hold it only weakly: more potent than IGF-1 in rats, cleared faster, and never given to a person in a published study. | The IGF-1 splice variant muscle makes after loading, sold online as a synthetic fragment that has never been given to a person in a study. |
| Mechanism | Activates the IGF-1 receptor while binding IGF-binding proteins only very weakly (PMID 8371075, 8708565), so more of each dose is free to act: infused continuously in rats it was generally 1.5- to 2-fold more potent than IGF-1 for weight gain, visceral organ weights and feed use, and it is cleared from the circulation faster (PMID 8708565). In animals it lowered blood glucose and insulin (calves, fetal sheep) and enlarged the gut, kidneys, spleen and adrenals without increasing body growth (guinea pigs). | MGF is generated by alternative splicing of the IGF-1 primary transcript following mechanical overload in skeletal muscle, producing an IGF-1 isoform with a unique C-terminal Ec extension. The Ec peptide appears to act independently of the IGF-1 receptor in the initial satellite-cell proliferation phase, while the IGF-1 portion of the full splice variant drives subsequent differentiation. Local, autocrine/paracrine action dominates — systemic administration of the unmodified peptide is largely ineffective because of near-immediate degradation. |
| Sources in the entry | 21 | 13 |
| Study cards | 15 | None (short entry) |
| Dosage page | None | None |
Two very different molecules
IGF-1 LR3 is IGF-1 with arginine at position 3 and a 13-amino-acid extension added to the front, 83 amino acids in all. The changes nearly abolish its binding to the IGF-binding proteins that normally hold IGF-1 in check; infused in rats it was 1.5 to 2 times as potent as IGF-1 and was cleared faster 1. It is made for research use; one recent study made it in yeast at gram-per-litre scale 2.
MGF, mechano growth factor, is something else. The IGF-1 gene can be spliced in several ways, and one version, IGF-1Ec, rises in muscle after injury. Its distinctive end piece, the E domain, has been made synthetically as a 24-amino-acid peptide, and that fragment, not a full growth factor, is what laboratories study 3.
What IGF-1 LR3 has been shown to do
IGF-1 LR3's studies are in animals. Infused for a week in guinea pigs, it did not change body weight gain, feed efficiency or carcass composition, though some organ weights increased 4. Injected in calves, it lowered the animals' own IGF-1 and growth hormone, and lowered blood glucose and insulin 5 6. In rats it increased intestinal glucose uptake 7, and in fetal sheep a short infusion lowered fetal insulin by 66% during a glucose clamp 8. None of this is a muscle-building result in adult animals, let alone in people.
Product quality is a separate problem. Researchers developing a doping test for IGF-1 analogues found oxidised, lower-quality peptide in black-market products 9. According to our entry, no published study has given IGF-1 LR3 to a person 1.
What MGF has been shown to do
MGF's evidence is thinner still. Applied to cultured human muscle cells from donors of different ages, the synthetic E peptide extended the proliferative lifespan of satellite cells from young donors but not old ones, and increased fibre growth in all cultures 10. In genetically modified mice, switching on extra MGF in the brain from an early age increased new neurons in the olfactory bulb in old age 11. The human studies measure the gene's expression in patients' tissue: in colorectal tissue, IGF-1Ec expression was higher in cancers and high-grade polyps than in normal colon 12. That is a reason for caution about a product sold to stimulate the same pathway, not evidence of benefit.
Risks both share
IGF-1Ec, the variant MGF comes from, is over-expressed in colorectal cancers and polyps, and has been reported in prostate and neuroendocrine tumours 12, which is reason for caution with anything sold to stimulate the pathway. In animal studies IGF-1 LR3 lowered blood glucose and insulin 6 8. Without human studies, nobody knows what doses, if any, are tolerated, how long they last in people or what they do over months. The approved drug in this family, recombinant human IGF-1 sold as mecasermin, is a different molecule, FDA-approved for severe primary IGF-1 deficiency 1.
How the differences add up (as of October 27, 2026)
IGF-1 LR3 is a potent research analogue with animal data and documented black-market quality problems; MGF is a synthetic fragment with cell and mouse data. Neither has been tested in people, neither is approved, and both are banned in sport 1. Our guide to reading a peptide study explains why a stack of animal studies is not evidence of a human benefit. The IGF-1 growth-factor peptides article adds IGF-1 DES and the low-blood-sugar risk the whole family shares.
Frequently asked questions
What is the difference between IGF-1 LR3 and MGF?
IGF-1 LR3 is a modified full-length IGF-1 that IGF-binding proteins bind only very weakly; MGF is a 24-amino-acid synthetic fragment from one splice variant of the IGF-1 gene.
Has IGF-1 LR3 been tested in humans?
No. According to our entry, no published study has given IGF-1 LR3 to a person; its studies are in animals and cells.
Is MGF the same as IGF-1?
No. MGF refers to the E-domain peptide of the IGF-1Ec splice variant, not the full IGF-1 hormone.
Related on Grey Peptides
Sources
- Grey Peptides dataset records for both compounds (IGF-1 LR3: 83 amino acids, a 13-residue N-terminal extension and arginine at position 3, nearly abolishing binding to IGF-binding proteins, 1.5 to 2 times as potent as IGF-1 when infused in rats and cleared faster; no human study of either; mecasermin FDA-approved for severe primary IGF-1 deficiency; WADA 2026 and 2027 S2.3); read October 27, 2026.
- Lu, Z., et al. (2023). Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Appl Microbiol Biotechnol, 107(14), 4543-4551. PMID: 37261455
- Vassilakos, G., et al. (2014). Biological activity of the e domain of the IGF-1Ec as addressed by synthetic peptides. Hormones (Athens), 13(2), 182-96. PMID: 24776619
- Conlon, M. A., et al. (1995). Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol, 146(2), 247-53. PMID: 7561636
- Hammon, H., et al. (1997). The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I. Am J Physiol, 273(1 Pt 1), E130-8. PMID: 9252489
- Hammon, H., et al. (1998). Endocrine and metabolic changes in neonatal calves in response to growth hormone and long-R3-insulin-like growth factor-I administration. Biol Neonate, 73(2), 121-8. PMID: 9483305
- Garnaut, S. M., et al. (2002). Effects of insulin-like growth factor-I and its analogue, long-R3-IGF-I, on intestinal absorption of 3-O-methyl-D-glucose are less pronounced than gut mucosal growth responses. Growth Factors, 20(1), 17-25. PMID: 11999215
- White, A., et al. (2023). Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. J Dev Orig Health Dis, 14(3), 353-361. PMID: 37114757
- Mongongu, C., et al. (2021). Detection of LongR(3) -IGF-I, Des(1-3)-IGF-I, and R(3) -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Test Anal, 13(7), 1256-1269. PMID: 33587816
- Kandalla, P. K., et al. (2011). Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev, 132(4), 154-62. PMID: 21354439
- Tang, J. J., et al. (2017). Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain. Mol Brain, 10(1), 23. PMID: 28683812
- Alagaratnam, S., et al. (2020). Increased expression of IGF-1Ec with increasing colonic polyp dysplasia and colorectal cancer. J Cancer Res Clin Oncol, 146(11), 2861-2870. PMID: 32772171
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead